Stellantis NV (8TI)
XETRA Stock Exchange · Germany · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 3.848 |
|---|---|
| 52-week range | 3.745 – 10.500 |
| Return, 1 month / 3 months | −8.0% / −24.5% |
| Return, 1 year / 3 years | −57.8% / −74.6% |
| Trend | Below its 200-day average |
| RSI (14) | 38 |
| Volatility (1 year) | 50.7% |
| Worst drawdown (1 year) | -63.2% |
| Average daily value traded | 2.58M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Stellantis is a carmaker formed by combining the Fiat Chrysler and PSA businesses, and it sells vehicles under brands such as Fiat, Peugeot, Citroen, Opel, Jeep, Ram and Alfa Romeo. Its customers are ordinary drivers, families and commercial fleets, and it offers passenger cars, light commercial vans, trucks and related parts and services. The company is based in the Netherlands, with large operations in France, Italy and the United States, and it sells vehicles in markets around the world.
On this site Stellantis NV appears as a stock on the XETRA Stock Exchange (Germany), code 8TI, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Stellantis NV (8TI) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 3.848 on 19 October 2026.
Its price-based Market X-Ray is 21 out of 100 (a weak price profile), ranking 620 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 57.8% and over the last three months it fell 24.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 6 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -34.2% | ||
| From 52-week high | -63.1% | ||
| Momentum | 6 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -24.5% | ||
| 6-month return | -46.5% | ||
| 12-month return, skipping the last month | -54.1% | ||
| Stability (higher is calmer) | 16 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 50.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -63.2% | ||
| Liquidity | 81 · Strong | Trades actively. | |
| Average daily value traded | 2.58M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −3.0% |
|---|---|
| 1 month | −8.0% |
| 3 months | −24.5% |
| 6 months | −46.5% |
| 1 year | −57.8% |
| 3 years | −74.6% |
| 5 years | −69.6% |
Signals
| 50-day / 200-day average | 4.326 / 5.850 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.159 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Apr 2025 | EUR 0.6800 |
| 22 Apr 2024 | EUR 1.5500 |
| 24 Apr 2023 | EUR 1.3400 |
| 19 Apr 2022 | EUR 1.0400 |
| 19 Apr 2021 | EUR 0.3200 |
| 15 Mar 2021 | EUR 0.1934 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.